Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimen

HIV Clin Trials. 2006 Jul-Aug;7(4):210-4. doi: 10.1310/hct0704-210.

Abstract

Purpose: To determine the long-term efficacy of a simplification strategy in the clinical setting when used to improve adherence.

Method: Prospective study of 70 patients included in a regimen with ddI plus 3TC plus an NNRTI, after viral suppression with a PI-containing regimen, due to decreasing adherence. Adherence to PI was calculated as the percentage of doses taken last week before inclusion, and patients were stratified as high and low adherence (95% and <95% of doses).

Results: Overall, 19 patients (27%) related adherence to PI <95% at inclusion (6 patients [9%], with adherence <80%). Mean adherence improved, with only 8% of patients presenting values <95%. At 104 weeks, 88% of patients on therapy had viral load suppression, but only 43% by ITT analysis. The main cause of therapy change or withdrawal was toxicity or drug interactions (26%). Notably, 16% of patients were lost to follow-up or left therapy, especially in the group of initially low adherent (26% vs. 12%, p = .02).

Conclusion: The use of a simplification strategy could be associated with long-term high risk of treatment failure, when used to improve adherence in the clinical setting.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Anti-Retroviral Agents / therapeutic use*
  • Anti-Retroviral Agents / toxicity
  • Didanosine / therapeutic use
  • Drug Interactions
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV Protease Inhibitors / toxicity
  • Humans
  • Lamivudine / therapeutic use
  • Male
  • Middle Aged
  • Patient Compliance*
  • Prospective Studies
  • Risk Factors
  • Treatment Failure

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • HIV Protease Inhibitors
  • Lamivudine
  • Didanosine